Montreal, March 20, 2018 – Oncopole and IRICoR have joined forces to launch the Fellowship Competition – Entrepreneurship in Oncology (CEO), and offer up-and-coming scientists the opportunity to participate in the first cohort of the new Life Sciences Entrepreneurship Development Program.
This hands-on, immersive program was launched by Montréal InVivo, Université de Montréal’s Faculty of Pharmacy and Concordia University’s John Molson Leadership Centre, in collaboration with IRICoR, with the aim of strengthening entrepreneurial skills in the life sciences. Program participants will benefit from over 150 hours of management training to enhance their knowledge of innovative business development strategies.
IRICoR and Oncopole are proud to announce the awarding of 8 fellowships to graduate students and postdoctoral fellows in oncology research: Nezahat Ozlem Arat (IRIC/UdeM); Simon Beaudoin (USherbrooke); Milad Dagher (McGillU); Jacqueline Ha (Jewish General Hospital, McGillU); Christina Mastromonaco (MUHC, McGillU); Laura Simon (IRIC/UdeM); Mona Wu (Jewish General Hospital, McGillU); and Yu Zhan (CRCHUM).
Nadine Beauger, IRICoR’s General Manager, would like to congratulate the recipients and is delighted that her organization is able to make a tangible contribution to the training of the next generation of scientists. “Developing entrepreneurial skills is at the heart of our industry’s future. I am convinced that the recipients of these first scholarships will make the most of the program, and will also mutually benefit from their already rich expertise.”
Stéphanie Lord-Fontaine, General Manager of Oncopole, underlines “the excellence and diversity of the candidates’ backgrounds”, and is convinced that “this will be a very dynamic cohort”.
About Oncopole
Oncopole is Quebec’s research, development and investment hub for accelerating the fight against cancer. Created in February 2017, it is the result of a unique co-creation process by the Fonds de recherche du Québec – Santé (FRQS) made possible by an initial investment of $15 million from Merck Canada. Oncopole’s mission is to act as a catalyst for the actions of Quebec’s oncology research and innovation ecosystem. The aim is to position the province as a leader in this field. Its priorities for action – research, entrepreneurship, the valorization and integration of innovation, and clinical relevance – are orchestrated to foster the mobilization of stakeholders, the discovery of innovative approaches to the fight against cancer and, ultimately, positive spin-offs for the benefit of patients. For more information on Oncopole, visit: oncopole.ca
AboutIRICoR ( Institute for Research in Immunology and Cancer – Commercialization of Research )
IRICoR, Université de Montréal’s drug discovery and maturation cluster, is a not-for-profit organization based at IRIC whose mandate is to accelerate the discovery, development and commercialization of new therapies in cancer, immunotherapy and related fields. Since its creation in 2008, IRICoR has successfully combined business expertise and industry-standard, cutting-edge research under one roof at an internationally recognized institute. IRICoR invests in and supports particularly innovative projects ensuring an efficient transition from basic research to innovative therapies that are more rapidly accessible to patients, through co-development partnerships with industry or the creation of spin-off companies. IRICoR gives selected academic projects access to an integrated drug discovery chain with one of the largest academic medicinal chemistry groups in Canada. For more information on IRICoR, visit: iricor.ca
